ライフサイエンスコーパス: D2 receptor antagonist

1 nsitive, calcium dependent, and blocked by a D2 receptor antagonist.

2 t of breast cancer, and (-)-IBZM, a dopamine D2 receptor antagonist.

3 ) and to systemic administration of DA D1 or D2 receptor antagonists.

4 ra-HPC carbachol or NMDA are not reversed by D2 receptor antagonists.

5 vity (S2 group) or with predominant dopamine D2 receptor antagonist activity (D2 group; HBBM, 40 mg,

6 ng task under the influence of either the DA D2 receptor antagonist amisulpride (400 mg), the NMDA re

7 and placebo controlled administration of the D2-receptor antagonist amisulpride.

8 ocker, was ineffective, as were sulpiride, a D2-receptor antagonist, and tertiapin, a G protein-coupl

9 a typical antipsychotic drug haloperidol, a D2 receptor antagonist, at a dose of 0.1 mg/kg, to incre

10 A D1, but not a D2, receptor antagonist attenuated both the C/L-DOPA-ind

11 ific D1 receptor agonist, SKF38393, no D1 or D2 receptor antagonists blocked the effect.

12 Intrashell microinfusion of a D1, but not a D2 receptor antagonist, blocks ICSS.

13 ty, a group of rats received the dopamine D1/D2 receptor antagonist cis-flupenthixol (0.5 mg/kg) 30 m

14 Both D1 and D2 receptor antagonists decreased the hyperactivity seen

15 acologic PRL mobilization using the dopamine D2 receptor antagonist domperidone prevented HCC in tumo

16 tor antagonist SCH 23390 (10 microm), or the D2 receptor antagonist eticlopride (20 microm).

17 The action of dopamine was blocked by the D2 receptor antagonist eticlopride, whereas a D1/5 antag

18 opamine D1 receptor agonist SKF-38393 or the D2 receptor antagonist eticlopride.

19 D(1) receptor antagonist SCH23390 or the DA D2 receptor antagonist eticlopride.

20 the 5-HT1A receptor agonist, 8-OH-DPAT, the D2 receptor antagonist, eticlopride, and the D1 receptor

21 The D2 receptor antagonist, eticlopride, blocked the ibogain

22 bilateral intra-amygdaloid infusions of the D2 receptor antagonist, eticlopride, on the acquisition

23 anaesthesia) administration of the dopamine D2 receptor antagonist haloperidol, but not raclopride (

24 the typical antipsychotic drug and dopamine D2 receptor antagonist haloperidol.

25 change the early-gene response elicited by a D2 receptor antagonist (haloperidol).

26 Interestingly, dopamine D1 and D2 receptor antagonists have opposite effects on plastic

27 e antipsychotic drug raclopride, a selective D2 receptor antagonist, increased phosphorylation of DAR

28 D1 receptor antagonist--but not dopaminergic D2 receptor antagonist--inhibited the TSD-mediated incre

29 Preincubation of (+)-butaclamol, a D2 receptor antagonist, inhibits both DA-stimulated tyro

30 effects whereas subeffective doses of the DA D2 receptor antagonist, L-741,626, rescued cocaine's abi

31 temic administration of a selective dopamine D2 receptor antagonist partially blocked the effects eli

32 atment for Tourette syndrome and primarily a D2 receptor antagonist, prevented D1 stimulation with SK

33 ctively, given that pretreatment with D1 and D2 receptor antagonists prevents the respective actions

34 Pretreatment with the dopamine D2 receptor antagonist raclopride (1mg/kg, ip) failed to

35 llenging them with the preferential dopamine D2 receptor antagonist raclopride and D1 receptor antago

36 usion of 10 microg (but not 2 microg) of the D2 receptor antagonist raclopride facilitated nursing bu

37 by their altered sensitivity to the dopamine D2 receptor antagonist raclopride.

38 The dopamine D2 receptor antagonist, raclopride, attenuated the actio

39 Positron emission tomography with the DA D2 receptor antagonist radiotracer [11C]raclopride detec

40 dol (0.2 mg/kg), relatively selective D1 and D2 receptor antagonists, respectively, blocked the AMPH-

41 Interestingly, 1 mum sulpiride, a D2 receptor antagonist, restored tLTP.

42 nist, SR141716A (5 mg/kg, i.p.), or dopamine D2 receptor antagonist, S(-)-raclopride (5 mg/kg, i.p.)

43 ter cAMP levels in other systems); 2) D1 and D2 receptor antagonists (SCH 23390, eticlopride, raclopr

44 rats were injected with the selective D1 or D2 receptor antagonists SCH23390 or eticlopride prior to

45 sing bilateral reverse microdialysis, D1 and D2 receptor antagonists (SCH23390, sulpiride) and the DA

46 We used the D2 receptor antagonist sulpiride and mice lacking the D2

47 This effect was completely reversed by the D2 receptor antagonist sulpiride but not by SCH 23390, a

48 By contrast, amphetamine and the D2 receptor antagonist sulpiride were without significan

49 hat was prevented by coadministration of the D2 receptor antagonist sulpiride.

50 receptor antagonist SCH23390 but not by the D2 receptor antagonist sulpiride.

51 The dopamine D2-receptor antagonist sulpiride decreases spontaneous l

52 Dopamine (D2) receptor antagonists were evaluated (Haloperidol [0.

53 It is the first non-D2 receptor antagonist with clear antipsychotic effects

54 n humans, we combined sulpiride, a selective D2 receptor antagonist, with the dopamine precursor l-DO